## ABSTRACT OF THE DISCLOSURE

Novel sulfate ester agents and the use of those agents for treating gastroesophageal reflux disease (GERD) are described, exemplary agents being of the formula:

wherein X is -OCH<sub>2</sub>- or -CH<sub>2</sub>O-; Y is a group pendant from X comprising at least one -OSO<sub>3</sub>R<sup>4</sup> moiety, wherein R<sup>4</sup> is H or a pharmaceutically acceptable cation; n is an integer from 1-3; and R<sup>1</sup> and R<sup>2</sup> are each independently selected from the group consisting of -H, a halogen with an atomic number from 9 to 53, -SO<sub>3</sub>R<sup>4</sup>, -NCS, -NCO, -NH(CO)-OR<sup>3</sup>, -NH(CS)SR<sup>3</sup>, -NH(C=NH)OR<sup>3</sup>, -NHCOCH<sub>2</sub>Cl, -NHCOCH<sub>2</sub>Br, -NHCO-CH=CH<sub>2</sub>, -NHC(O)-CF<sub>3</sub>, wherein R<sup>4</sup> is H or a pharmaceutically acceptable cation.